AlphAIalphai — Financial news for AI agents
financialcontent.comAUG 64 min read$AMPH

Amphastar Pharmaceuticals (NASDAQ:AMPH) Posts Better

Amphastar Pharmaceuticals (NASDAQ:AMPH) reported Q2 2026 results with revenue up 5.4% year on year to $183.9 million, exceeding Wall Street estimates by 2%, according to the company. Non-GAAP adjusted EPS was $0.91, up from $0.85, and 48.3% above consensus. The stock rose 4.5% to $20.70 after the release.

Original reporting
financialcontent.com
Published Aug 6, 2026, 10:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 10:19 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Amphastar Pharmaceuticals (NASDAQ:AMPH) Posts Better — source image
Source · financialcontent.com
Decision brief

The 30-second read

$AMPHBullishMed
01

Why it matters

Traders can use the Q2 beat plus the margin and forward EPS signals to reassess near-term earnings quality and the sustainability of growth.

02

Market read

Q2 results beat revenue and adjusted EPS, but margin contraction and expected full-year EPS decline introduce a two-sided setup for AMPH positioning.

03

What to watch

Forward full-year EPS is expected to shrink 5.7% (from $2.99 to $2.82), which could cap upside despite the Q2 beat.

Relevance 8/10Novelty 7/10Timing: post-Q2 results, after-hours/next-session positioning

Background

Amphastar is a specialty pharma focused on technically challenging injectables and inhalation products, with both generic and proprietary pipelines.

Company-level read

Ticker impact

$AMPHBullishMedium confidence
Context

Amphastar reported Q2 CY2026 revenue of $183.9M (+5.4% YoY) and adjusted EPS of $0.91, both beating consensus.

Expected impact

Likely modest positive follow-through versus peers, with traders watching whether margin pressure reverses in subsequent quarters.

Evidence & confidence

The article provides concrete Q2 beat figures and a same-day stock pop, but also notes adjusted operating margin fell YoY and full-year EPS is expected to decline.

Market effects

Sector

Reinforces demand resilience for specialty injectables, but margin compression highlights competitive and pricing pressure in pharma.

Regional

Limited, primarily affects US small/mid-cap pharma sentiment.

Global

Low; no international regulatory or product-trial developments cited.

Counterpoint

What could challenge this read

The headline beat may be less durable given the article’s note of decelerating revenue growth and a YoY adjusted operating margin decline.

Key entities

  • company
    Amphastar Pharmaceuticals

    Reported Q2 CY2026 revenue and adjusted EPS results, with commentary on strategy execution and margin trends.

  • executive
    Dr. Jack Zhang

    CEO who attributed results to execution of long-term strategy and progress across product launches and pipelines.

Read at source← All news

Related articles

AUG 14
$AMPHMedAI 8/10

Amphastar (AMPH) Q2 2026 Earnings Call Transcript

Amphastar (AMPH) reported Q2 2026 net revenues of $183.9 million, up 5% from $174.4 million, and gross margin of 50.8% versus 49.6%. GAAP net income was $30.3 million ($0.67/share). Adjusted non-GAAP net income was $40.8 million ($0.91/share). IMS remediation tied to an FDA warning letter is expected to add $2 million to $3 million per quarter, while full-year sales growth guidance remains mid-single digit to high single digit.

fool.com6 min
AUG 6
$AMPHMed

Amphastar Pharmaceuticals, Inc. (AMPH): Results of Operations and Financial Condition

Amphastar Pharmaceuticals, Inc. (AMPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 amph-20260806xex99d1.htm EX-99.1 EXHIBIT 99.1 ​ Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026 ​ - Net revenues of $183.9 million for the three months ended June 30, 2026 ​ - GAAP net income of $30.3 million, or $0.67 per sh

SEC EDGAR 8-K7 min
JUL 9
$AMPHMedAI 8/10

A New Over-the-Counter Naloxone Nasal Spray Is Now Available at Pharmacies

The FDA approved Rextovy, a 4 mg naloxone hydrochloride nasal spray by Amphastar Pharmaceuticals, for over-the-counter sale on June 16, 2026. It joins Narcan (Emergent BioSolutions) and RiVive (Harm Reduction Therapeutics) as OTC naloxone options. The article cites overdose-death figures and says expanded access may affect retail pricing and availability.

medicaldaily.com5 min
JUN 10
$AMPHMed

Amphastar Pharmaceuticals Pivots to Proprietary Drugs, Biosimilars for Growth

Amphastar Pharmaceuticals said it is leaning more on proprietary drugs and biosimilars to drive growth, while keeping BAQSIMI and Primatene MIST as key branded products. In Phase 1, AMP-101 (intranasal epinephrine) and other early programs include AMP-105/109 oncology and AMP-107 for wet AMD. The company forecasts BAQSIMI peak sales of $250–$275M and peak incremental adjusted EPS of $2–$2.50, and Primatene MIST sales of $109M last year with high-single-digit growth. Amphastar reported $285M cash

finance.yahoo.com7 min
JUN 2
$AMPHMedAI 8/10

Amphastar Pharmaceuticals, Inc. (AMPH) Price Target Cut to $21 At Piper Sandler Amid Pipeline Uncertainty

Piper Sandler cut its price target for Amphastar Pharmaceuticals (NASDAQ: AMPH) from $25 to $21 while keeping a Neutral rating, TheFly reported May 11. The firm cited limited visibility on when pipeline programs will produce meaningful results. Amphastar’s May 7 Q1 ended March 31, 2026 net revenues were $171.2M; GAAP EPS $0.14 and adjusted EPS $0.42.

finance.yahoo.com4 min
AUG 14
$MDLNMed

Medline (MDLN) Q2 2026 Earnings Call Transcript

Medline (MDLN) Q2 2026 call said adjusted EBITDA rose 13% YoY to $1.1B, with higher costs partly offset by a $243M IEEPA tariff refund benefit. Q2 net sales grew 12% to $7.7B. Company raised fiscal 2026 organic sales outlook, but moderated adjusted EBITDA outlook citing Middle East conflict, Tracy warehouse fire, investments, quality remediation, and retail softness.

yahoo.com7 min